脓毒症后的医疗费用:一项系统评价
该研究为系统评价,检索MEDLINE、Embase、CINAHL和Cochrane数据库2000年至2025年2月4日的文献,纳入23项观察性研究,评估发达国家成年脓毒症幸存者出院后的医疗费用。结果发现费用计算方法差异大;出院后第一年中位总医疗费用为28,719美元(IQR 21,715美元),第二年为22,460美元(IQR 14,407美元),脓毒症再入院中位费用为20,320美元(IQR 4,889美元);7项含非脓毒症对照的研究中6项报告脓毒症幸存者出院后费用更高。结论指出脓毒症幸存者出院后费用高昂且可持续数年。
要点
- 脓毒症幸存者出院后第一年中位总医疗费用为28,719美元(IQR 21,715美元)。
- 出院后第二年中位总医疗费用为22,460美元(IQR 14,407美元),费用负担持续存在。
- 脓毒症幸存者再入院的中位费用为20,320美元(IQR 4,889美元)。
- 7项含非脓毒症对照的研究中6项报告脓毒症幸存者出院后医疗费用高于无脓毒症者。
- 各研究费用计算方法和报告期间差异很大,费用构成包括再入院、医生就诊、药物费用等。
适用人群与场景
- 居住在发达国家的成年脓毒症幸存者,即经历过一次脓毒症发作后存活出院的成人。
研究设计与关键结果
- 研究类型为系统评价,纳入23项观察性研究,使用Newcastle-Ottawa量表评估非随机研究质量,采用叙述性综合总结结果。
- 检索MEDLINE、Embase、CINAHL和Cochrane Central Register of Controlled Trials及Database of Systematic Reviews,时间从2000年至2025年2月4日。
- 出院后第一年中位总医疗费用为28,719美元(IQR 21,715美元)。
- 出院后第二年中位总医疗费用为22,460美元(IQR 14,407美元)。
- 脓毒症幸存者再入院的费用中位数为20,320美元(IQR 4,889美元)。
- 7项包含非脓毒症对照组的研中,6项报告脓毒症幸存者出院后医疗费用高于无脓毒症个体。
- 各研究计算和报告医疗费用的方法差异很大,包括费用类型(再入院、医生就诊、药物费用等)和费用计算期间。
证据类型、等级与局限
- 证据类型为系统评价,纳入23项观察性研究,采用Newcastle-Ottawa量表评估非随机研究质量。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为这些发现强调脓毒症的长期健康经济负担,突出脓毒症是政策和实践干预的重要目标,可能改善健康结局并降低成本。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis is a life-threatening syndrome associated with significant health resource utilization. Previous systematic reviews have demonstrated high healthcare costs during hospitalization with sepsis, but post-discharge health costs have not been characterized. Understanding these costs allows health system decision-makers to identify targets for reducing preventable spending and strain on healthcare resources. This systematic review aims to describe the post-hospitalization healthcare costs among adults living in developed nations who survived an episode of sepsis.
METHODS: We searched MEDLINE, Embase, CINAHL, and the Cochrane Central Register of Controlled Trials and Database of Systematic Reviews from the year 2000 to February 4, 2025. The search strategy was developed by combining concepts of sepsis, costs, study types, and developed countries. Two reviewers independently screened titles and abstracts, followed by full-text review and data extraction. Conflicts were resolved by a third reviewer. Study quality was assessed using the Newcastle-Ottawa scale for non-randomized studies. Narrative synthesis was used to summarize findings.
RESULTS: We identified 23 observational studies that met the inclusion criteria. The methods used to calculate and report healthcare costs varied widely across studies, including the types of costs incurred (readmissions, physician visits, medication costs, and others) and the period over which costs were calculated. Across studies, the median total healthcare cost among sepsis survivors in year one after discharge was $28,719 (IQR $21,715) and the median total healthcare cost in year two after discharge was $22,460 (IQR $14,407). The median cost of a readmission for sepsis survivors was $20,320 (IQR $4,889). Six of seven studies that included a non-sepsis comparator group reported that sepsis survivors accrue higher healthcare costs post-discharge compared to individuals without sepsis.
CONCLUSIONS: Our systematic review demonstrates that sepsis survivors incur high healthcare costs that can persist for years after discharge from initial hospitalization. These findings underscore the long-term health economic burden of sepsis, highlighting sepsis as an important target for policy and practice interventions that could improve health outcomes and reduce costs.
PROSPERO REGISTRATION NUMBER: CRD42023456850.
参考来源
- Chechulina V, Sheikh F, Lóser M, et al. Healthcare costs after sepsis: a systematic review. Crit Care. 2025. PMID: 40846957. doi:10.1186/s13054-025-05600-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。